Senior Editor – Europe
Latest From David Ridley
Germany's Ministry of Health surprised all those present at a recent BAH meeting by announcing it would like to see erectile dysfunction drugs like sildenafil and tadalafil available OTC. Such a move, however, would put the government at odds with drug regulator BfArM's Expert Committee for Prescription, which recently rejected an application for the Rx-to-OTC switch of sildenafil.
Futura Medical is preparing to seek approval from the FDA to launch OTC in the US its MED3000 erectile dysfunction treatment, marketed in Europe under the Eroxon brand name. After completing all the necessary studies demonstrating that the gel-based, drug-free product works as a self-care treatment for ED, Futura says it is confident that the soon to be submitted de novo medical device application will be successful and pave the way for a Q1 2023 launch.
More medicines available without a prescription and more responsibility for community pharmacists are two of the goals set out by the UK's new Secretary of State for Health and Social Care.
Haleon’s Puraflor probiotic when taken daily by adults was shown to alter gray matter volume and brain response patterns, according to a study published in the journal Cells.
Bayer UK sees the recent launch of Berocca Immuno as a step towards "mega-brand" status for its line of effervescent VMS tablets.
Two new RCTs cast further doubt on the preventative effects of vitamin D supplementation with regards to COVID-19 infection. Nevertheless, an editorial in the British Medical Journal, where the studies were published, leaves open positive effects for those suffering from vitamin D deficiency, and recommends a daily supplement of up to 2000IU just in case.